PCRX vs. NATH

Last updated Jun 4, 2026

PCRX (Pacira BioSciences, Inc.) and NATH (Nathan's Famous, Inc.) are both stocks. PCRX operates in Drug Manufacturers - Specialty & Generic (Healthcare), while NATH operates in Restaurants (Consumer Cyclical). Over the past 10 years, PCRX returned -7.19%/yr vs 11.84%/yr for NATH. At a 0.14 correlation, their price movements are largely independent.

Performance

PCRX vs. NATH - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Pacira BioSciences, Inc. (PCRX) and Nathan's Famous, Inc. (NATH). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, PCRX achieves a -13.76% return, which is significantly lower than NATH's 8.65% return. Over the past 10 years, PCRX has underperformed NATH with an annualized return of -7.19%, while NATH has yielded a comparatively higher 11.84% annualized return.

PCRX

• 1D: 0.31%
• 1M: -9.60%
• YTD: -13.76%
• 6M: -7.73%
• 1Y: -15.45%
• 3Y*: -17.04%
• 5Y*: -18.20%
• 10Y*: -7.19%

NATH

• 1D: 0.17%
• 1M: 0.90%
• YTD: 8.65%
• 6M: 8.25%
• 1Y: 0.64%
• 3Y*: 13.26%
• 5Y*: 11.43%
• 10Y*: 11.84%

*Multi-year figures are annualized to reflect compound growth (CAGR)

PCRX vs. NATH - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
PCRX Pacira BioSciences, Inc.	-13.76%	37.37%	-44.16%	-12.61%	-35.83%	0.55%	32.10%	5.30%	-5.76%	41.33%
NATH Nathan's Famous, Inc.	8.65%	24.58%	3.51%	19.24%	18.67%	8.05%	-20.24%	8.66%	-11.19%	23.77%

Correlation

The correlation between PCRX and NATH is 0.21, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.21
Correlation (3Y) Calculated over the trailing 3-year period	0.17
Correlation (5Y) Calculated over the trailing 5-year period	0.15
Correlation (10Y) Calculated over the trailing 10-year period	0.16
Correlation (All Time) Calculated using the full available price history since Feb 4, 2011	0.14

Fundamentals

Market Cap PCRX : $913.11M NATH : $416.68M
EPS PCRX : $0.21 NATH : $5.20
PE Ratio PCRX : 104.26 NATH : 19.45
PS Ratio PCRX : 1.32 NATH : 2.64
Total Revenue (TTM) PCRX : $734.86M NATH : $157.78M
Gross Profit (TTM) PCRX : $427.72M NATH : $48.04M
EBITDA (TTM) PCRX : $95.04M NATH : $32.46M

Return for Risk

PCRX vs. NATH — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PCRX

PCRX Risk / Return Rank: 22
PCRX Sharpe Ratio Rank: 23
PCRX Sortino Ratio Rank: 23
PCRX Omega Ratio Rank: 23
PCRX Calmar Ratio Rank: 23
PCRX Martin Ratio Rank: 19

NATH

NATH Risk / Return Rank: 39
NATH Sharpe Ratio Rank: 42
NATH Sortino Ratio Rank: 35
NATH Omega Ratio Rank: 36
NATH Calmar Ratio Rank: 41
NATH Martin Ratio Rank: 40

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

PCRX vs. NATH - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Pacira BioSciences, Inc. (PCRX) and Nathan's Famous, Inc. (NATH). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	PCRX	NATH	Difference
Sharpe ratio Return per unit of total volatility	-0.42	0.02	-0.44
Sortino ratio Return per unit of downside risk	-0.36	0.23	-0.59
Omega ratio Gain probability vs. loss probability	0.96	1.03	-0.07
Calmar ratio Return relative to maximum drawdown	-0.52	0.03	-0.56
Martin ratio Return relative to average drawdown	-1.07	0.06	-1.13
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

PCRX vs. NATH - Sharpe Ratio Comparison

The current PCRX Sharpe Ratio is -0.42, which is lower than the NATH Sharpe Ratio of 0.02. The chart below compares the historical Sharpe Ratios of PCRX and NATH, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	PCRX	NATH	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.42	0.02	-0.44
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.40	0.41	-0.81
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.15	0.36	-0.52
Sharpe Ratio (All Time) Calculated using the full available price history	0.16	0.23	-0.07

Drawdowns

PCRX vs. NATH - Drawdown Comparison

The maximum PCRX drawdown since its inception was -90.19%, which is greater than NATH's maximum drawdown of -76.16%. Use the drawdown chart below to compare losses from any high point for PCRX and NATH.

Drawdown Indicators

	PCRX	NATH	Difference
Max Drawdown Largest peak-to-trough decline	-90.19%	-76.16%	-14.03%
Max Drawdown (1Y) Largest decline over 1 year	-29.61%	-19.52%	-10.09%
Max Drawdown (3Y) Largest decline over 3 years	-71.53%	-22.62%	-48.91%
Max Drawdown (5Y) Largest decline over 5 years	-85.67%	-35.27%	-50.40%
Max Drawdown (10Y) Largest decline over 10 years	-85.67%	-53.17%	-32.50%
Current Drawdown Current decline from peak	-81.29%	-8.96%	-72.33%
Average Drawdown Average peak-to-trough decline	-50.01%	-32.19%	-17.82%
Ulcer Index Depth and duration of drawdowns from previous peaks	14.42%	10.80%	+3.62%

Volatility

PCRX vs. NATH - Volatility Comparison

Pacira BioSciences, Inc. (PCRX) has a higher volatility of 10.03% compared to Nathan's Famous, Inc. (NATH) at 1.41%. This indicates that PCRX's price experiences larger fluctuations and is considered to be riskier than NATH based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	PCRX	NATH	Difference
Volatility (1M) Calculated over the trailing 1-month period	10.03%	1.41%	+8.62%
Volatility (6M) Calculated over the trailing 6-month period	28.70%	12.41%	+16.29%
Volatility (1Y) Calculated over the trailing 1-year period	37.03%	26.82%	+10.21%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	45.60%	28.09%	+17.51%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	46.90%	32.83%	+14.07%

Dividends

PCRX vs. NATH - Dividend Comparison

PCRX has not paid dividends to shareholders, while NATH's dividend yield for the trailing twelve months is around 4.45%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
NATH Nathan's Famous, Inc.	4.45%	4.81%	2.54%	2.56%	2.68%	2.40%	2.54%	1.83%	1.13%	6.62%	0.00%	48.49%
PCRX Pacira BioSciences, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials

PCRX vs. NATH - Profitability Comparison

The chart below illustrates the profitability comparison between Pacira BioSciences, Inc. and Nathan's Famous, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

PCRX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Pacira BioSciences, Inc. reported a gross profit of 0.00 and revenue of 177.38M. Therefore, the gross margin over that period was 0.0%.

NATH - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Nathan's Famous, Inc. reported a gross profit of 11.17M and revenue of 34.31M. Therefore, the gross margin over that period was 32.6%.

PCRX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Pacira BioSciences, Inc. reported an operating income of 6.90M and revenue of 177.38M, resulting in an operating margin of 3.9%.

NATH - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Nathan's Famous, Inc. reported an operating income of 5.13M and revenue of 34.31M, resulting in an operating margin of 14.9%.

PCRX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Pacira BioSciences, Inc. reported a net income of 7.08M and revenue of 177.38M, resulting in a net margin of 4.0%.

NATH - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Nathan's Famous, Inc. reported a net income of 3.08M and revenue of 34.31M, resulting in a net margin of 9.0%.

Frequently Asked Questions

Can I hold both PCRX and NATH in my portfolio?

PCRX and NATH have a correlation of 0.21, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, PCRX or NATH?

PCRX has higher volatility (10.03%) compared to NATH (1.41%). In terms of maximum drawdown, PCRX dropped -90.19% vs NATH's -76.16%.

Which has better risk-adjusted returns?

NATH currently has the higher Sharpe Ratio (0.02 vs -0.42), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.